7 October 2024
Staying on top of the latest advances in the HIV prevention field is key for communities, researchers, funders, implementers, ministries of health, and other stakeholders—but how can one navigate the vast amount of online pre-exposure prophylaxis (PrEP) data?
This poster, presented at the HIVR4P conference in Lima (Peru) in October 2024, describes the uses and complementarities of two databases compiling information on PrEP research, development, access, and uptake at both country and global levels: LAPaL (developed by the Medicines Patent Pool), and PrEPWatch (developed by AVAC).
LAPaL and PrEPWatch are complementary evidence-based free online tools designed to increase transparency and information sharing on HIV prevention. The platforms support the audience to navigate curated data, news, infographics, guidelines, clinical trials, regulatory approvals, tracking tools and other resources to help the global community speed the delivery of accessible PrEP methods to everyone who needs them.
The platforms are evolving and will be improved in their next iterations, including with updated national guidelines and the addition of more long-acting technologies and compounds of potential impact in low- and middle-income countries.
AVAC receives support for PrEPWatch from various sources including the Gates Foundation, the Children’s Investment Fund Foundation and PEPFAR through USAID, via the MOSAIC consortium.
LAPaL is sponsored by Unitaid and through LEAP, by the NIH. LAPaL is part of the MPP-powered PaL ecosystem, providing insights on patents, licences, clinical and regulatory intelligence. More information on MedsPaL, the other MPP-powered PaL tool.
Download the poster
Access LAPaL
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada, the World Intellectual Property Organization (WIPO) and the Government of Flanders. MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.